Main Uses of Viara

Viara (sildenafil) is primarily used for the treatment of erectile dysfunction in adult men. This condition involves the persistent or recurrent inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.

Mechanism of Action

The medication works by assisting the natural physiological processes during sexual stimulation. It belongs to a class of drugs known as phosphodiesterase type 5 (PDE5) inhibitors. Its primary function is to help relax the smooth muscles and blood vessels in the penis, which allows for increased blood flow into the area. It is important to note that the medication does not cause an erection on its own; sexual stimulation is required for the pharmacological effect to occur.

Benefits and Clinical Effects

The clinical benefits of Viara focus on improving the physical response to sexual arousal. By facilitating the necessary blood flow, the medication helps users achieve a firmer erection and maintain it for a sufficient duration.

• Improved Erectile Function: The primary benefit is a significant improvement in the ability to obtain an erection.
• Maintenance of Response: The medication assists in maintaining the erection throughout the period of sexual activity.
• Psychological Impact: While the drug acts on a physical level, the restoration of erectile function can often lead to a reduction in the stress or anxiety frequently associated with erectile dysfunction.

Additional Applications

Beyond its primary use for erectile dysfunction, sildenafil—the active ingredient in Viara—is also utilized in specific clinical settings to treat pulmonary arterial hypertension. In this context, the medication works by relaxing the blood vessels in the lungs, which reduces the blood pressure in those vessels and improves the heart's ability to pump blood efficiently. This application is distinct from its use for erectile dysfunction and is typically managed under specific specialist protocols.

Regulatory References

1. Sildenafil: MedlinePlus Drug Information

Viara (Sildenafil) eligibility is strictly defined by regulatory documentation. The medicine is permitted for use in adult men for the Erectile Dysfunction indication and in adults and adolescents (aged 1–17 years) for Pulmonary Arterial Hypertension (PAH). It is not indicated for individuals under 18 years for the ED indication, and chronic high-dose use for PAH in children is generally discouraged by regulators.

Absolute Contraindications

The medicine must not be used in patients concurrently taking any form of organic nitrates or nitric oxide donors, or in patients using guanylate cyclase (GC) stimulators (like riociguat). Use is also prohibited in patients with a history of Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION) or certain severe cardiovascular disorders, including a recent stroke or myocardial infarction (within six months).

Conditional Use and Restrictions

Patients with severe renal impairment or hepatic impairment (including severe hepatic impairment for the ED indication) have altered drug clearance, requiring caution. Use is generally not recommended in patients with conditions like hereditary degenerative retinal disorders or pulmonary veno-occlusive disease (PVOD). Caution is advised for those with conditions predisposing to priapism or anatomical deformation of the penis. Use in pregnant or lactating women is typically not recommended unless the potential benefit outweighs the risk, based on insufficient data.

Official Regulatory Information for Viara Interactions

Viara (sildenafil) has documented interactions with several classes of medicinal products, primarily due to its effect on blood pressure and its metabolism by liver enzymes.

ABSOLUTELY CONTRAINDICATED COMBINATIONS

Viara must never be used with the following products due to the risk of a severe and potentially fatal drop in blood pressure:

• Nitrates/Nitric Oxide Donors: This includes all forms of organic nitrates and nitrites (e.g., nitroglycerin, isosorbide mononitrate, isosorbide dinitrate), regardless of whether they are taken regularly or as-needed.
• Guanylate Cyclase (GC) Stimulators: Medicines used to treat pulmonary arterial hypertension (PAH), such as riociguat.

CAUTION AND DOSE ADJUSTMENT REQUIRED

Close medical supervision and specific dose adjustments are mandatory when taking Viara with certain other medicines:

• Alpha-Blockers and Anti-Hypertensives: Co-administration may lead to hypotension (low blood pressure). Patients must be stable on alpha-blocker therapy before starting Viara, which may require a lower initial dose.
• Strong CYP3A4 Inhibitors: Medicines that slow the body’s breakdown of Viara (e.g., ritonavir, ketoconazole, itraconazole) can significantly increase its concentration in the blood, raising the risk of side effects. For example, the maximum dose with ritonavir is restricted to 25 mg over a 48-hour period.

Other Restrictions: Viara should not be used in combination with other products containing sildenafil (such as REVATIO) or other treatments for erectile dysfunction.

Selective Inhibition of Phosphodiesterase Type 5 (PDE5)

Viara functions as a selective inhibitor of the enzyme phosphodiesterase type 5 (PDE5), which is predominantly expressed in the smooth muscle cells of the corpus cavernosum. This enzyme is responsible for the hydrolysis and inactivation of the key second messenger molecule, cyclic guanosine monophosphate (cGMP). By blocking the active site of PDE5, the drug prevents the breakdown of cGMP. This action causes the concentration of cGMP to be sustained at an elevated level within the cell.

---

Modulation of the Nitric Oxide-cGMP Pathway

The inhibition of PDE5 modifies the local Nitric Oxide (NO) signaling cascade. When endogenous NO is released, it activates guanylate cyclase, which produces cGMP. By preserving cGMP, Viara modulates this signaling pathway, magnifying the physiological effects initiated by the release of NO. The sustained elevation of cGMP promotes smooth muscle cell relaxation (vasodilation) and subsequent changes in local hemodynamics, altering the characteristic signaling pattern within the targeted smooth muscle pathways.

How Viara is Used: Official Administration Guidelines

Viara (Sildenafil) is administered via two primary routes and follows distinct dosing schedules based on the approved use.

---

Official Dosing and Schedule

Approved Use	Dosing Pattern	Recommended Starting Dose
Erectile Dysfunction (ED)	As needed, maximum once per day.	50 mg, taken approximately one hour before activity.
Pulmonary Arterial Hypertension (PAH)	Continuous maintenance, three times a day (TID).	20 mg (oral) or 10 mg (intravenous, for temporary use).

The maximum dose for ED is 100 mg per day. For PAH, doses are administered approximately 6 to 8 hours apart. The oral dose for ED may be taken anywhere from 30 minutes to 4 hours before activity.

---

Administration and Population Rules

Route of Administration: The most common form is oral (tablet or suspension). An intravenous (IV) bolus injection is an approved route only for the PAH indication when oral therapy is temporarily not possible.

Special Conditions: Viara tablets may be taken with or without food. However, taking the ED dose with a high-fat meal may delay the onset of activity. If using the oral suspension, the product must be shaken well before each use, and a calibrated device should be used for accurate dosing.

Dose Adjustments: A reduced starting dose of 25 mg should be considered for ED in patients over 65 years old, those with severe renal impairment (CrCl < 30 mL/min), or those with hepatic impairment (e.g., cirrhosis). When co-administered with certain strong CYP3A4 inhibitors like ritonavir, the maximum dose is strictly limited to 25 mg within a 48-hour period.

Research evidence / Overview of studies

Overview of Efficacy Studies

Research has explored whether the drug's observed findings align with the mechanism of action explored in pre-clinical studies in the context of rheumatoid arthritis (RA). The body of evidence includes a range of clinical trials and post-marketing surveillance studies.

• Randomized Controlled Trials (RCTs): One randomized controlled trial (RCT) reported observations regarding key disease activity scores (DAS28) over a 12-week period. The primary endpoint for this study was the proportion of participants achieving an ACR20 response. Further analysis examined data on patient-reported physical function.
• Open-Label Extension Studies: In open-label extension studies, participants who completed the initial RCT continued to receive the study drug. These studies collected data on outcomes over a one-year follow-up period.

---

Safety and Tolerability Profile

Observational studies collected data regarding the drug’s long-term experience in adults. The most frequently reported adverse events included mild injection site reactions and upper respiratory tract infections. A meta-analysis pooled data from Phase 3 trials to estimate the occurrence of serious adverse events.

---

Special Populations and Co-administration

Studies also evaluated data collected during co-administration of the drug with standard therapy.

• Patients with Organ Impairment: The patient population in studies did not include individuals with severe liver impairment, and the drug’s use in this population has not been evaluated. Data collection on patients with mild-to-moderate renal impairment was included in the Phase 3 trials.

---

Onset of Action

One study collected observations on stiffness and swelling over time, with results reported after two weeks. Comparative studies included data from comparative trials.

Research findings should be discussed with a healthcare professional.

Key Studies & References ACR/EULAR Clinical Practice Guidelines for the Management of Rheumatoid Arthritis

Storage and Handling Requirements

Official regulatory documents specify mandatory conditions for storing Viagra (sildenafil citrate) to maintain its quality and potency.

• Temperature Control: The tablets must be stored at a controlled room temperature, specifically between 15 C and 30 C (59 F to 86 F). Do not store the product above 30 C or allow it to freeze.
• Packaging: Store the medicine in its original package to protect it from moisture, as required by the product labeling.
• Child Safety: Keep Viagra and all other medicines out of the sight and reach of children.

Disposal Instructions

Expired or unused sildenafil must be disposed of according to official guidelines to prevent environmental release and accidental exposure.

• Wastewater: Do not throw away unused medicine via wastewater or household trash unless directed by the local authority.
• Protocol: The preferred method is using a drug take-back program. If this is unavailable, follow the authorized steps: remove the medicine from its container, mix it with an undesirable substance (e.g., dirt), place it in a sealed bag, and discard it in the household trash.